Objective: Poloxamer-188 is a synthetic, organic compound that acts by binding hydrophobic pockets on damaged lipid bilayers in the circulation. P-188 reduces blood viscosity and confers anti-inflammatory and cytoprotective effects. Vepoloxamer (Mast Therapeutics, San Diego, Calif) is a purified version of this compound that has limited side effects. The aim of this study was to investigate drug interactions between vepoloxamer and heparin and tissue plasminogen activator (tPA).
Poloxamer-188 (P-188) is a triblock organic, synthetic, and amphipathic molecule composed of a hydrophobic core, flanked by two hydrophilic side chains. Its mean molecular mass is about 8500 daltons, but it ranges from 7680 to 9510 daltons. In the circulation, it binds to hydrophobic pockets at sites of lipid membrane damage. 1 This underlying activity has been shown to protect cells, to prevent cellular adhesion, to reduce blood viscosity, and to exert overall anticoagulative, anti-inflammatory, and cytoprotective effects. 1-3 P-188 does not act through specific receptor binding affinity. Rather, it changes the way that blood components and the endothelium interact with water, ultimately reducing adhesive interactions and improving blood flow.
2,4-6
However, low-molecularweight components of P-188 associated with its manufacture have been shown to result in renal dysfunction, preventing its application in the clinical setting.
Vepoloxamer is a purified version of P-188 (Mast Therapeutics, San Diego, Calif), with mean molecular mass of 8400 6 750 daltons, that has displayed minimal renal side effects and has similar hemorheologic benefit regarding both the improvement of blood flow and the reduction of inflammation. 7 Vepoloxamer is a rheologic agent. As such, it may be administered in the setting of other common hemodynamic-modifying or anticoagulant agents and has been previously shown to increase blood flow and to reduce inflammation in many clinical settings of circulatory compromise, such as myocardial infarction, cutaneous burns, and ischemia-reperfusion neuronal injuries in strokes.
Smaller successful studies have led to a multicenter, phase 3, double-blind, randomized clinical trial, the Evaluation of Purified Poloxamer 188 (MST-188) In Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) study, to determine if vepoloxamer can reduce the duration of vaso-occlusive crisis in patients with sickle cell anemia. 8, 9 The aim of this study was to determine if these intrinsic anticoagulant and anti-inflammatory effects of vepoloxamer potentiate the effects of heparin and tissue plasminogen activator (tPA) through interaction.
METHODS
In vivo rat models. A well-established tail transection model was used to investigate the in vivo interaction between heparin and vepoloxamer. 10 Under general anesthesia, saline (1 mL/kg) or vepoloxamer (25 mg/kg) was administered to Sprague-Dawley rats through tail vein injection. After a 5-minute circulation time, the rats were treated with saline, low-dose heparin (125 mg/kg), or highdose heparin (250 mg/kg) for a total of six treatment groups with six rats in each group. After an additional 5 minutes, the distal 2 mm of the tail (more peripheral to the intravenous drug administration site) was transected with a scalpel. Bleeding was assessed every 30 seconds using filter paper, and the time to clot formation was measured as bleeding time. Rat blood was obtained through cardiac puncture when clot formation was established. A previously validated crush-induced internal jugular vein (IJV) thrombosis model was used to investigate the in vivo interaction between tPA and vepoloxamer. 11, 12 Under general anesthesia, the neck was shaved, and a 1-inch vertical incision was made on the neck to expose the IJV. Smooth-tipped mosquito forceps were used to clamp the IJV for 1 minute. Blood flow was monitored using a continuous-wave Doppler probe for 5 minutes. This process was repeated until IJV thrombosis was confirmed by the absence of blood flow determined by the Doppler probe. Saline or vepoloxamer (25 mg/kg) was administered through tail vein injection. After 5 minutes, the rats were treated with saline, low-dose (0.5 mg/kg) tPA, or high-dose tPA (1 mg/kg) for a total of six treatment groups. Six rats were treated in each group for a total of 36 rats. Blood flow was measured for 15 minutes after the administration of tPA. If lysis (detection of blood flow with Doppler) occurred before 15 minutes, the time of lysis was recorded. No flow up to 15 minutes was recorded as no lysis. A citrated blood sample was obtained by cardiac puncture 15 minutes after tPA injection whether lysis was observed or not. This blood was used for ex vivo standardized clotting tests.
Ex vivo studies. In the IJV thrombolysis model, cardiac puncture was performed exactly 15 minutes after the tail vein injection of tPA, regardless of study outcome (clot lysis). The plasma of each rat in the IJV thrombolysis model was subjected to three standardized clotting tests: prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT) with 5 U/mL calcium chloride.
In vitro human plasma studies. Normal human plasma (NHP) was obtained from healthy volunteers and screened for common coagulopathies including von Willebrand disease, hemophilia A, and hemophilia B. NHP was supplemented with vepoloxamer to make concentrations of 0.1, 1, and 10 mg/mL. The same three standardized clotting tests were run on each sample: PT, aPTT, and TT. A concentration curve of heparin was made in both pooled NHP samples with the following concentrations of heparin: 0.3, 0.6, 1.2, and 2.5 mg/mL. Each NHP sample was divided in half. Vepoloxamer was added to half of each sample for a 10% final concentration of the volume, and the other half was used as a saline control. The same standardized clotting tests were run on these samples: PT, aPTT, and TT.
The fibrokinetics, or fibrin formation dynamics, procedure was run using the SpectraMax 364 spectrophotometer (Molecular Devices, Sunnyvale, Calif). NHP was supplemented with vepoloxamer to make concentrations of 0.1, 1, and 10 mg/mL. Fibrin formation was assessed on these samples and on a saline control at a wavelength of 405 nm for 30 minutes, assessed every 30 seconds.
Statistical analysis. The bleeding time data from the rat tail transection model were analyzed using a t-test based on heparin dosing; groups with the same dose of heparin with and without vepoloxamer treatment were compared. The clot lysis data from the IJV thrombolysis model were analyzed using a Fisher exact test based on tPA dosing; groups with the same dose of tPA with and without vepoloxamer treatment were compared. The data from the standardized clotting tests performed on the rat blood obtained from the IJV thrombolysis model were analyzed using t-tests; this also compared groups with the same dose of tPA with and without vepoloxamer.
RESULTS

In vivo interaction of heparin and vepoloxamer.
Compared with saline, vepoloxamer increased bleeding time (10.3 vs 7.1 minutes; P ¼ .001; Table I ). When vepoloxamer was combined with low-dose heparin (125 mg/kg), bleeding time was also increased compared with low-dose heparin alone (14.2 vs 6.2 minutes; P < .001). There was no change in bleeding time when vepoloxamer was added to high-dose heparin (250 mg/kg;
vs 17.0 minutes).
In vivo interaction of tPA and vepoloxamer. Vepoloxamer by itself did not demonstrate thrombolytic properties. It did, however, tend to potentiate the effects of low-dose tPA (0.5 mg/kg); IJV thrombolysis was observed in four of six rats treated with vepoloxamer at low-dose tPA compared with none of six rats treated with low-dose tPA alone (P ¼ .06). Thrombolytic activity at high-dose tPA (1.0 mg/kg) was not further enhanced by vepoloxamer (Table II) .
Ex vivo studies. Vepoloxamer had no effects on PT and did not potentiate the effects of tPA on PT (Table III) . It tended to increase aPTT (13.8 vs 18.2 seconds; P ¼ .053) but did not further enhance tPA-mediated prolongation of aPTT (Table IV) . Vepoloxamer alone exhibited no effects on TT. Vepoloxamer did mitigate the tPAmediated prolongation of TT in the setting of high-dose tPA only (35.7 vs 29.6 seconds; P ¼ .01; Table V) .
In vitro studies with human plasma. In pooled NHP without added heparin, vepoloxamer had no effects on PT or aPTT, whereas it decreased TT in a dosedependent manner (Fig 1) . When added to heparinized human plasma, vepoloxamer had no effects on PT (Fig 2, a) . However, it mitigated heparin-mediated prolongation of aPTT at high doses (Fig 2, b) . It also mitigated effects of moderately high concentrations of heparin (1.25 mg/mL). The limits of the TT test were reached in the setting of 2.5 mg/mL of heparin (Fig 2, c) .
The fibrokinetics study showed that the addition of vepoloxamer resulted in a concentration-related Vepoloxamer has no effect on PT or aPTT.
increase in both the rate of fibrin formation (rate of change in optical density) and the maximal optical density reached by fibrin-based clot formation (Fig 3) . Because thrombin is added in excess in this test, fibrinogen is the limiting reagent. This implies that the increase in optical density is caused by an increase in size of the fibrin molecules in the presence of vepoloxamer.
DISCUSSION
This study suggests that the combination of vepoloxamer with both low-dose tPA and low-dose heparin may improve the efficacy of these agents. Although the small sample size and limited concentration range studied did not allow conclusions about the potential synergy between vepoloxamer and heparin, this study did demonstrate that vepoloxamer in the setting of lowdose tPA has potential to cause thrombolysis equally effective as high-dose tPA. This potentiation of lowdose tPA has not been previously reported and has numerous clinical implications.
This study did not identify additional anticoagulation or thrombolysis associated with vepoloxamer in the setting of higher doses of heparin or tPA, which may indicate that vepoloxamer does not increase bleeding risk. To date, no bleeding complications have been reported in clinical studies investigating vepoloxamer in sickle cell disease patients with vaso-occlusive crisis. 13, 14 In standardized clotting tests on both rat and human plasma, vepoloxamer had little effect on PT or aPTT even at a suprapharmacologic concentration of 10.0 mg/mL. However, in the TT assay, vepoloxamer displayed an apparent paradoxical effect in that it resulted in a concentration-dependent shortening of the 5 U/mL TT. The fibrokinetic assay demonstrated a similar profile in that vepoloxamer increased the rate of fibrin formation and the final size of the fibrin fibers as measured by changes in optical density. The fibrokinetic data also offer an explanation to the TT paradox. Because fibrinogen is the limiting reagent in the fibrokinetic assay, these observations may indicate that vepoloxamer has few or no effects on thrombin or thrombin generation, and its effect on shortening of the TT (and acceleration of the fibrokinetic assay) is a result of an acceleration of the polymerization of fibrin monomers by thicker fibrin fibers. This is consistent with studies reported by Carr et al 15 and van Gelder et al 16 demonstrating that fibrin assembly and structure were altered in the presence of P-188. The potential mechanism of vepoloxamer for facilitating thrombolysis deserves a comment. Vepoloxamer has no direct mechanical effect on the thrombus. Rather, it alters the rheology of blood by lowering viscosity, which improves flow through microchannels in the thrombus. This, in turn, increases delivery of plasminogen activators (to clot-bound plasminogen) with enhanced removal of fibrin degradation products through a flowrelated mechanism. 17 In the presence of vepoloxamer, accelerated fibrin polymerization results in increased fibrin fiber size, which results in a fibrin network more permeable to t-PA. 15, 16 Because the occlusive thrombi were formed before the administration of vepoloxamer in this study, the enhanced thrombolysis with tPA most likely resulted from increased blood flow. However, because thrombosis is a dynamic process with clots forming and lysing, it may also be possible that any new thrombus formed in the presence of vepoloxamer was more permeable, which may have contributed to increased fibrinolysis. Additional studies would be needed to investigate this hypothesis. There are several limitations to this study. Because of the limitations of collecting blood from rats at various time points and the impact of pharmacokinetics of vepoloxamer on the intended end points, 18 ex vivo standardized coagulation tests from the heparin-treated rats of the tail transection model on the effects of vepoloxamer on platelet function and the interaction between tPA and vepoloxamer could not be conducted. These studies would have provided important context about the relationships between the bleeding time end point and laboratory assessment of anticoagulant activity. Small sample size is another limitation; a larger sample size would have reduced variability and random error within the data.
CONCLUSIONS
Vepoloxamer shows few intrinsic anticoagulant effects but may potentiate the action of heparin. This suggests that less heparin may lead to clinically acceptable anticoagulation in patients receiving vepoloxamer therapy. Vepoloxamer also potentiates the activity of tPA through rheologic effects in the circulation but also by altering fibrin molecules, making them more susceptible to lysis by tPA. Through these actions, vepoloxamer may enable less tPA in the clinical setting. These properties of vepoloxamer may improve efficacy of heparin and tPA and reduce costs. Additional studies are needed to verify these observations.
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To date, the use of anticoagulants to prevent thromboembolism and recurrent thrombosis in the arterial and venous circulation has been plagued by a very real and problematic attendant risk of bleeding. Whereas the advent of the direct oral anticoagulants has provided a breakthrough in convenience for the patient, the true "Holy Grail" of anticoagulant therapy is to establish a way to prevent pathologic thrombosis with minimal or no bleeding risk. Major bleeding rates for low-molecularweight heparin approximate 2%, and even for the direct oral anticoagulants, major and clinically nonmajor bleeding may be as high as 8% to 10%. 1, 2 As such, this work represents a priority issue in anticoagulation pharmacology. If vepoloxamer allows a lower dose of heparin to be used and potentiation of tissue plasminogen activator, then the use of such a compound could have significant clinical impact and benefit. Importantly, this medication has been shown to be safe in phase I and II trials (albeit for different indications) and thus represents a tangible and realistic translation of bench research.
Although this work is interesting and potentially important, areas that need to be clarified include the dose of heparin that was used and how it relates to clinical dosage (the amount of heparin in the current study seems to be low compared with what is clinically used in patients although previously used in other rat studies) and the establishment of parameters by which to monitor the effect of the drug with standard tests. Nonetheless, the data are provocative and the concept an important one. We should all applaud the efforts to look at improving the safety of patients by decreasing dosages of anticoagulants and fibrinolytic agents while maintaining therapeutic efficacy.
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